Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib plus FOLFIRINOX as First Line Therapy for Advanced Pancreatic Cancer

By
Justin.choi
-
0
11
Actuate Therapeutics, Inc. announced the opening of a randomized study of elraglusib plus FOLFIRINOX alone or with Losartan for patients with advanced pancreatic cancer in the first-line setting.
[Actuate Therapeutics, Inc. (Globe Newswire, Inc.)]

Sorry, but the selected Zotpress account can't be found.

Press Release